{"transactions":[{"id":1479820,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2024-06-14T20:20:58.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":49933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":49933,"derivative":{"exercise_price":6.3,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":49933},"source":{"system":"sec-edgar","filing":"0001127602-24-018708","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224018708/form4.xml","form_type":"4"}},{"id":1479819,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:20:58.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":6820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":70159,"source":{"system":"sec-edgar","filing":"0001127602-24-018708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224018708/form4.xml","form_type":"4"}},{"id":1499644,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-29T20:16:35.000Z","date":"2024-05-24","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":6.4,"value":16000.0,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001127602-24-016776","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224016776/form4.xml","form_type":"4"}},{"id":1735104,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2023-11-20T17:09:40.000Z","date":"2023-11-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":483741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-020445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000089924323020445/doc4.xml","form_type":"4"}},{"id":1855066,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2023-06-15T20:39:06.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":39072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":39072,"derivative":{"exercise_price":8.18,"exercise_date":"2024-06-13","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":39072},"source":{"system":"sec-edgar","filing":"0001127602-23-018786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223018786/form4.xml","form_type":"4"}},{"id":1855065,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-15T20:39:06.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":16745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":63339,"source":{"system":"sec-edgar","filing":"0001127602-23-018786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223018786/form4.xml","form_type":"4"}},{"id":1950643,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-16T16:30:19.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, which is made as part of the Issuer's 2023 annual compensation cycle, vests and becomes exercisable in full on March 14, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-019300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919123019300/doc4.xml","form_type":"4"}},{"id":2100372,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-01T16:01:54.000Z","date":"2022-11-29","kind":"purchase","acquired":true,"shares":409836,"price":1.22,"value":499999.92,"ownership":{"direct":true},"balance_after":483741,"source":{"system":"sec-edgar","filing":"0001209191-22-059172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919122059172/doc4.xml","form_type":"4"}},{"id":2238271,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2022-06-09T20:36:14.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":30022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":30022,"derivative":{"exercise_price":10.79,"exercise_date":"2023-06-07","expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":30022},"source":{"system":"sec-edgar","filing":"0001127602-22-017138","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222017138/form4.xml","form_type":"4"}},{"id":2238270,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-09T20:36:14.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":12866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":46594,"source":{"system":"sec-edgar","filing":"0001127602-22-017138","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222017138/form4.xml","form_type":"4"}},{"id":2248260,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-02T20:43:06.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":569,"price":9.31,"value":5297.39,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022."}],"balance_after":33728,"source":{"system":"sec-edgar","filing":"0001127602-22-016409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222016409/form4.xml","form_type":"4"}},{"id":2273419,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T00:35:33.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":2575,"price":21.9249,"value":56456.6175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":146919,"source":{"system":"sec-edgar","filing":"0001209191-22-028702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028702/doc4.xml","form_type":"4"}},{"id":2362817,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-03-02T21:34:42.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":301,"price":16.61,"value":4999.61,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":33159,"source":{"system":"sec-edgar","filing":"0001127602-22-007717","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222007717/form4.xml","form_type":"4"}},{"id":2432766,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-19T16:15:05.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 14, 2023."}],"balance_after":18500,"derivative":{"exercise_price":2.21,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-22-003708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919122003708/doc4.xml","form_type":"4"}},{"id":2476070,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T16:02:42.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":7984,"price":2.04,"value":16287.36,"ownership":{"direct":true},"balance_after":73905,"source":{"system":"sec-edgar","filing":"0001209191-21-069227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919121069227/doc4.xml","form_type":"4"}},{"id":2476069,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-13T16:02:42.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":2016,"price":2.15,"value":4334.4,"ownership":{"direct":true},"balance_after":65921,"source":{"system":"sec-edgar","filing":"0001209191-21-069227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919121069227/doc4.xml","form_type":"4"}},{"id":2489707,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-12-02T21:15:38.000Z","date":"2021-11-30","kind":"grant","acquired":true,"shares":414,"price":12.06,"value":4992.84,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":32858,"source":{"system":"sec-edgar","filing":"0001127602-21-030063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221030063/form4.xml","form_type":"4"}},{"id":2504674,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-18T21:08:44.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":31800,"price":29.39,"value":934602.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.05 to $29.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 19,500 shares previously reported as indirectly held in the name of the Aselage Family Trust."}],"balance_after":149494,"source":{"system":"sec-edgar","filing":"0001209191-21-065439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121065439/doc4.xml","form_type":"4"}},{"id":2519513,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-11-09T21:05:36.000Z","date":"2021-11-05","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":70000,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-063591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121063591/doc4.xml","form_type":"4"}},{"id":2519512,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T21:05:36.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":10000,"price":26.23,"value":262300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":161794,"source":{"system":"sec-edgar","filing":"0001209191-21-063591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121063591/doc4.xml","form_type":"4"}},{"id":2519511,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T21:05:36.000Z","date":"2021-11-05","kind":"exercise","acquired":true,"shares":10000,"price":16.23,"value":162300.0,"ownership":{"direct":true},"balance_after":171794,"source":{"system":"sec-edgar","filing":"0001209191-21-063591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121063591/doc4.xml","form_type":"4"}},{"id":2526069,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-11-02","kind":"sale","acquired":false,"shares":3500,"price":30,"value":105000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the name of the Aselage Family Trust."}],"balance_after":19500,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2526068,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":5000,"price":29.48,"value":147400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.065 to $29.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the name of the Aselage Family Trust."}],"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2526067,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-07-16","kind":"gift","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the name of the Aselage Family Trust."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2526066,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-07-16","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":161794,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2526065,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-02-04","kind":"gift","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held in the name of the Aselage Family Trust."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2526064,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:05:54.000Z","date":"2021-02-04","kind":"gift","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":164794,"source":{"system":"sec-edgar","filing":"0001209191-21-062670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121062670/doc4.xml","form_type":"4"}},{"id":2545440,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-10-08T20:18:33.000Z","date":"2021-10-07","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":80000,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-060035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121060035/doc4.xml","form_type":"4"}},{"id":2545439,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-08T20:18:33.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":32000,"price":26.26,"value":840320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":189794,"source":{"system":"sec-edgar","filing":"0001209191-21-060035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121060035/doc4.xml","form_type":"4"}},{"id":2545438,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-08T20:18:33.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":28000,"price":26.23,"value":734440.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":221794,"source":{"system":"sec-edgar","filing":"0001209191-21-060035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121060035/doc4.xml","form_type":"4"}},{"id":2545437,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-08T20:18:33.000Z","date":"2021-10-07","kind":"exercise","acquired":true,"shares":60000,"price":16.23,"value":973800.0,"ownership":{"direct":true},"balance_after":249794,"source":{"system":"sec-edgar","filing":"0001209191-21-060035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121060035/doc4.xml","form_type":"4"}},{"id":2582606,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-02T20:28:26.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":314,"price":15.92,"value":4998.88,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":32444,"source":{"system":"sec-edgar","filing":"0001127602-21-024772","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221024772/form4.xml","form_type":"4"}},{"id":2690010,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-01T20:16:05.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":634,"price":15.77,"value":9998.18,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000."}],"balance_after":32130,"source":{"system":"sec-edgar","filing":"0001127602-21-018470","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018470/form4.xml","form_type":"4"}},{"id":2694225,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-05-27T20:16:40.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":13.28,"exercise_date":"2022-05-25","expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-21-018174","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018174/form4.xml","form_type":"4"}},{"id":2707796,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-05-19T01:21:05.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":18.27,"exercise_date":"2022-05-14","expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-033851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121033851/doc4.xml","form_type":"4"}},{"id":2707795,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T01:21:05.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":189794,"source":{"system":"sec-edgar","filing":"0001209191-21-033851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121033851/doc4.xml","form_type":"4"}},{"id":2714338,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T20:05:33.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":2146,"price":19.582,"value":42022.972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":186794,"source":{"system":"sec-edgar","filing":"0001209191-21-032312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121032312/doc4.xml","form_type":"4"}},{"id":2743926,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-04-20T20:05:46.000Z","date":"2021-04-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":140000,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-027558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121027558/doc4.xml","form_type":"4"}},{"id":2743925,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T20:05:46.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":10000,"price":26.23,"value":262300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":188940,"source":{"system":"sec-edgar","filing":"0001209191-21-027558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121027558/doc4.xml","form_type":"4"}},{"id":2743924,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T20:05:46.000Z","date":"2021-04-16","kind":"exercise","acquired":true,"shares":10000,"price":16.23,"value":162300.0,"ownership":{"direct":true},"balance_after":198940,"source":{"system":"sec-edgar","filing":"0001209191-21-027558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121027558/doc4.xml","form_type":"4"}},{"id":2777503,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-03-19T20:05:44.000Z","date":"2021-03-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":150000,"derivative":{"exercise_price":16.23,"expiration_date":"2026-05-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-022056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121022056/doc4.xml","form_type":"4"}},{"id":2777502,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T20:05:44.000Z","date":"2021-03-17","kind":"sale","acquired":false,"shares":7727,"price":27.56,"value":212956.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.025 to $28.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":188940,"source":{"system":"sec-edgar","filing":"0001209191-21-022056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121022056/doc4.xml","form_type":"4"}},{"id":2777501,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T20:05:44.000Z","date":"2021-03-17","kind":"sale","acquired":false,"shares":10000,"price":27.35,"value":273500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":196667,"source":{"system":"sec-edgar","filing":"0001209191-21-022056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121022056/doc4.xml","form_type":"4"}},{"id":2777500,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T20:05:44.000Z","date":"2021-03-17","kind":"exercise","acquired":true,"shares":10000,"price":16.23,"value":162300.0,"ownership":{"direct":true},"balance_after":206667,"source":{"system":"sec-edgar","filing":"0001209191-21-022056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121022056/doc4.xml","form_type":"4"}},{"id":2823005,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-02T21:47:59.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":927,"price":10.78,"value":9993.06,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000."}],"balance_after":31496,"source":{"system":"sec-edgar","filing":"0001127602-21-008747","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221008747/form4.xml","form_type":"4"}},{"id":2885411,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2021-02-03T02:18:32.000Z","date":"2021-02-21","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable."}],"balance_after":275000,"derivative":{"exercise_price":10.09,"expiration_date":"2024-11-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-007023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007023/doc4.xml","form_type":"4"}},{"id":2885410,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-03T02:18:32.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":25000,"price":30.75,"value":768750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":196667,"source":{"system":"sec-edgar","filing":"0001209191-21-007023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007023/doc4.xml","form_type":"4"}},{"id":2885409,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-03T02:18:32.000Z","date":"2021-02-02","kind":"exercise","acquired":true,"shares":25000,"price":10.09,"value":252250.0,"ownership":{"direct":true},"balance_after":221667,"source":{"system":"sec-edgar","filing":"0001209191-21-007023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007023/doc4.xml","form_type":"4"}},{"id":2903003,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-20T16:10:48.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 15, 2022."}],"balance_after":15000,"derivative":{"exercise_price":3.85,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-004261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919121004261/doc4.xml","form_type":"4"}},{"id":2942354,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-17T01:55:58.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":5549,"price":26.02,"value":144384.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":196667,"source":{"system":"sec-edgar","filing":"0001209191-20-063929","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120063929/doc4.xml","form_type":"4"}},{"id":2956512,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-05T00:00:08.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":7891,"price":23.4253,"value":184849.0423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.42 to $23.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":202216,"source":{"system":"sec-edgar","filing":"0001209191-20-061869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120061869/doc4.xml","form_type":"4"}},{"id":2956511,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-05T00:00:08.000Z","date":"2020-11-19","kind":"gift","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":210107,"source":{"system":"sec-edgar","filing":"0001209191-20-061869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120061869/doc4.xml","form_type":"4"}},{"id":2961779,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-12-02T21:19:44.000Z","date":"2020-11-30","kind":"grant","acquired":true,"shares":1956,"price":5.11,"value":9995.16,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000."}],"balance_after":30569,"source":{"system":"sec-edgar","filing":"0001127602-20-030289","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030289/form4.xml","form_type":"4"}},{"id":2989636,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-07T01:56:51.000Z","date":"2020-11-06","kind":"sale","acquired":false,"shares":20625,"price":23,"value":474375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":213107,"source":{"system":"sec-edgar","filing":"0001209191-20-057381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120057381/doc4.xml","form_type":"4"}},{"id":2989635,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-07T01:56:51.000Z","date":"2020-11-05","kind":"sale","acquired":false,"shares":2500,"price":21.26,"value":53150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":233732,"source":{"system":"sec-edgar","filing":"0001209191-20-057381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120057381/doc4.xml","form_type":"4"}},{"id":3041865,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-09-02T20:36:57.000Z","date":"2020-08-31","kind":"grant","acquired":true,"shares":2409,"price":4.15,"value":9997.35,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000."}],"balance_after":28613,"source":{"system":"sec-edgar","filing":"0001127602-20-024642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220024642/form4.xml","form_type":"4"}},{"id":3065808,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T20:07:37.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2500,"price":19.68,"value":49200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":236232,"source":{"system":"sec-edgar","filing":"0001209191-20-045456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120045456/doc4.xml","form_type":"4"}},{"id":3075050,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T09:02:48.000Z","date":"2020-07-24","kind":"purchase","acquired":true,"shares":45000,"price":3.5,"value":157500.0,"ownership":{"direct":true},"balance_after":63905,"source":{"system":"sec-edgar","filing":"0001209191-20-043805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919120043805/doc4.xml","form_type":"4"}},{"id":3097492,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T01:02:45.000Z","date":"2020-06-25","kind":"sale","acquired":false,"shares":10000,"price":20,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":238732,"source":{"system":"sec-edgar","filing":"0001209191-20-039338","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120039338/doc4.xml","form_type":"4"}},{"id":3125456,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-03T20:24:32.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":1112,"price":4.495,"value":4998.44,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":26204,"source":{"system":"sec-edgar","filing":"0001127602-20-018719","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220018719/form4.xml","form_type":"4"}},{"id":3142525,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2020-05-20T00:00:12.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9000,"derivative":{"exercise_price":15.43,"exercise_date":"2021-05-15","expiration_date":"2030-05-14","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-030744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120030744/doc4.xml","form_type":"4"}},{"id":3142524,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T00:00:12.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":248732,"source":{"system":"sec-edgar","filing":"0001209191-20-030744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120030744/doc4.xml","form_type":"4"}},{"id":3148794,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T00:59:21.000Z","date":"2020-05-14","kind":"sale","acquired":false,"shares":3062,"price":15.09,"value":46205.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":245732,"source":{"system":"sec-edgar","filing":"0001209191-20-029410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/doc4.xml","form_type":"4"}},{"id":3148793,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T00:59:21.000Z","date":"2020-05-13","kind":"sale","acquired":false,"shares":4063,"price":16.41,"value":66673.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":248794,"source":{"system":"sec-edgar","filing":"0001209191-20-029410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/doc4.xml","form_type":"4"}},{"id":3148792,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T00:59:21.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1000,"price":17.16,"value":17160.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":252857,"source":{"system":"sec-edgar","filing":"0001209191-20-029410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/doc4.xml","form_type":"4"}},{"id":3149735,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2020-05-14T20:18:22.000Z","date":"2020-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":5.41,"exercise_date":"2021-05-12","expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-20-016559","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220016559/form4.xml","form_type":"4"}},{"id":3159359,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-06T20:09:04.000Z","date":"2020-05-05","kind":"sale","acquired":false,"shares":2500,"price":15.88,"value":39700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":253857,"source":{"system":"sec-edgar","filing":"0001209191-20-027448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120027448/doc4.xml","form_type":"4"}},{"id":3220332,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-10T01:03:43.000Z","date":"2020-03-05","kind":"sale","acquired":false,"shares":4359,"price":15.3564,"value":66938.5476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":256357,"source":{"system":"sec-edgar","filing":"0001209191-20-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120017537/doc4.xml","form_type":"4"}},{"id":3220331,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-10T01:03:43.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 24,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled."}],"balance_after":260716,"source":{"system":"sec-edgar","filing":"0001209191-20-017537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120017537/doc4.xml","form_type":"4"}},{"id":3235149,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-03-03T21:59:16.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":1666,"price":3,"value":4998.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":25092,"source":{"system":"sec-edgar","filing":"0001127602-20-009094","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220009094/form4.xml","form_type":"4"}},{"id":3284397,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-08T00:38:38.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":2500,"price":16.62,"value":41550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":248466,"source":{"system":"sec-edgar","filing":"0001209191-20-007720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120007720/doc4.xml","form_type":"4"}},{"id":3324133,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T16:13:21.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on January 2, 2021."}],"balance_after":9000,"derivative":{"exercise_price":3.79,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-000860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919120000860/doc4.xml","form_type":"4"}},{"id":3355093,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-12-03T22:14:26.000Z","date":"2019-12-01","kind":"grant","acquired":true,"shares":1754,"price":2.85,"value":4998.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":23426,"source":{"system":"sec-edgar","filing":"0001127602-19-034168","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219034168/form4.xml","form_type":"4"}},{"id":3356692,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-30T02:27:11.000Z","date":"2019-11-29","kind":"sale","acquired":false,"shares":5000,"price":13.9105,"value":69552.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price and includes 4,933 shares sold at $13.91 per share and 67 shares sold at $13.95 per share."}],"balance_after":250966,"source":{"system":"sec-edgar","filing":"0001209191-19-058446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119058446/doc4.xml","form_type":"4"}},{"id":3369130,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-11-18T21:01:05.000Z","date":"2019-11-18","kind":"purchase","acquired":true,"shares":15000,"price":1.45,"value":21750.0,"ownership":{"direct":true},"balance_after":21672,"source":{"system":"sec-edgar","filing":"0001127602-19-033001","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219033001/form4.xml","form_type":"4"}},{"id":3423970,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-09-04T20:14:44.000Z","date":"2019-09-01","kind":"grant","acquired":true,"shares":1672,"price":2.99,"value":4999.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000."}],"balance_after":6672,"source":{"system":"sec-edgar","filing":"0001127602-19-027867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219027867/form4.xml","form_type":"4"}},{"id":3467076,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-05T16:08:19.000Z","date":"2019-07-03","kind":"purchase","acquired":true,"shares":5000,"price":3.7162,"value":18581.0,"ownership":{"direct":true},"balance_after":18905,"source":{"system":"sec-edgar","filing":"0001209191-19-041332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919119041332/doc4.xml","form_type":"4"}},{"id":3506813,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2019-05-31T20:13:59.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":30000,"derivative":{"exercise_price":2.91,"exercise_date":"2020-05-29","expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-19-020302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219020302/form4.xml","form_type":"4"}},{"id":3512606,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-24T20:20:00.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":3000,"price":3.57,"value":10710.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-19-019891","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219019891/form4.xml","form_type":"4"}},{"id":3523730,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-17T01:34:49.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":1838,"price":17.82,"value":32753.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $17.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":255966,"source":{"system":"sec-edgar","filing":"0001209191-19-030657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030657/doc4.xml","form_type":"4"}},{"id":3523729,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-17T01:34:49.000Z","date":"2019-05-14","kind":"sale","acquired":false,"shares":1838,"price":17.79,"value":32698.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.74 to $17.90,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":257804,"source":{"system":"sec-edgar","filing":"0001209191-19-030657","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030657/doc4.xml","form_type":"4"}},{"id":3531427,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee stock option (right to buy)","published_at":"2019-05-11T00:32:39.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8000,"derivative":{"exercise_price":17.94,"exercise_date":"2020-05-08","expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-19-029151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029151/doc4.xml","form_type":"4"}},{"id":3531426,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-11T00:32:39.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":259642,"source":{"system":"sec-edgar","filing":"0001209191-19-029151","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029151/doc4.xml","form_type":"4"}},{"id":3596190,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-03-14T20:18:39.000Z","date":"2019-03-12","kind":"purchase","acquired":true,"shares":2000,"price":8.3,"value":16600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.21 to $8.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001127602-19-011361","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219011361/form4.xml","form_type":"4"}},{"id":3660269,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-02-14T01:47:03.000Z","date":"2019-02-12","kind":"sale","acquired":false,"shares":1065,"price":21.5,"value":22897.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":257642,"source":{"system":"sec-edgar","filing":"0001209191-19-009924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119009924/doc4.xml","form_type":"4"}},{"id":3660268,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2019-02-14T01:47:03.000Z","date":"2019-02-11","kind":"sale","acquired":false,"shares":1065,"price":21.38,"value":22769.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":258707,"source":{"system":"sec-edgar","filing":"0001209191-19-009924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119009924/doc4.xml","form_type":"4"}},{"id":3675169,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-02-05T13:50:22.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on February 1, 2020."}],"balance_after":6000,"derivative":{"exercise_price":24.46,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-007239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919119007239/doc4.xml","form_type":"4"}},{"id":3701158,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true}}],"security":"Non-Qualified Stock Option","published_at":"2019-01-08T18:23:24.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan."}],"balance_after":25000,"derivative":{"exercise_price":8.62,"exercise_date":"2020-01-04","expiration_date":"2029-01-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001127602-19-001582","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219001582/form4.xml","form_type":"4"}},{"id":3721248,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:20:27.000Z","date":"2018-12-21","kind":"sale","acquired":false,"shares":900,"price":22.3456,"value":20111.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2850 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":259772,"source":{"system":"sec-edgar","filing":"0001209191-18-064022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/doc4.xml","form_type":"4"}},{"id":3721247,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:20:27.000Z","date":"2018-12-21","kind":"sale","acquired":false,"shares":5288,"price":21.6941,"value":114718.4008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.1975,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":260672,"source":{"system":"sec-edgar","filing":"0001209191-18-064022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/doc4.xml","form_type":"4"}},{"id":3721246,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:20:27.000Z","date":"2018-12-20","kind":"sale","acquired":false,"shares":6188,"price":21.9713,"value":135958.4044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $22.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":265960,"source":{"system":"sec-edgar","filing":"0001209191-18-064022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/doc4.xml","form_type":"4"}},{"id":3723282,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-21T00:56:51.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":20625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 41,250 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled."}],"balance_after":272148,"source":{"system":"sec-edgar","filing":"0001209191-18-063772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118063772/doc4.xml","form_type":"4"}},{"id":3739364,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-08T02:15:31.000Z","date":"2018-12-07","kind":"sale","acquired":false,"shares":10,"price":24.0374,"value":240.374,"ownership":{"direct":true},"balance_after":251523,"source":{"system":"sec-edgar","filing":"0001209191-18-061669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118061669/doc4.xml","form_type":"4"}},{"id":3739363,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-12-08T02:15:31.000Z","date":"2018-11-29","kind":"gift","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":251533,"source":{"system":"sec-edgar","filing":"0001209191-18-061669","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118061669/doc4.xml","form_type":"4"}},{"id":3760828,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:14.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":1086,"price":24.7514,"value":26880.0204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":253283,"source":{"system":"sec-edgar","filing":"0001209191-18-059063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/doc4.xml","form_type":"4"}},{"id":3760827,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:14.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":4464,"price":24.2134,"value":108088.6176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.65 to $24.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":254369,"source":{"system":"sec-edgar","filing":"0001209191-18-059063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/doc4.xml","form_type":"4"}},{"id":3760826,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:14.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":600,"price":24.575,"value":14745.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":258833,"source":{"system":"sec-edgar","filing":"0001209191-18-059063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/doc4.xml","form_type":"4"}},{"id":3760825,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:14.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":4950,"price":23.6343,"value":116989.785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $24.07,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":259433,"source":{"system":"sec-edgar","filing":"0001209191-18-059063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/doc4.xml","form_type":"4"}},{"id":3764533,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-11-15T01:42:49.000Z","date":"2018-11-09","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2015, the reporting person was granted performance restricted stock units (PRSUs) covering 37,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner."}],"balance_after":264383,"source":{"system":"sec-edgar","filing":"0001209191-18-058647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118058647/doc4.xml","form_type":"4"}},{"id":3828655,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":89908,"kind":"person","name":"ASELAGE STEVE","position":1,"cik":"0001221599","reported_name":"ASELAGE STEVE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2018-08-31T23:54:32.000Z","date":"2018-08-31","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":8.7,"exercise_date":"2013-12-06","expiration_date":"2023-12-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-049134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118049134/doc4.xml","form_type":"4"}}],"next_cursor":"2018-08-31T23:54:32.000000Z,3828655"}